⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440057 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL9978262 | 0.98 | LOXL2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL2408796 | 0.98 | LOXL2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL31083599 | 0.98 | LOXL2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL1413792 | 0.98 | LOXL2 (0.41) | — | |
| SCHEMBL12496499 | 0.83 | MAOB (0.42) | — | |
| SCHEMBL29791989 | 0.82 | HRH1 (0.47) | — | |
| SCHEMBL475520 | 0.82 | HRH1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL3938820 | 0.80 | HRH1 (0.45) | — | |
| Hydrochloric Acid SCHEMBL3239050 | 0.80 | HRH1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| CN-119431371-B | Beta-carbolin 3,6, 9-modified derivative and preparation method and application thereof | 沈阳药科大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12527775-B2 | Heteroaromatic derivatives having serotonin receptor binding activity | SHIONOGI & CO., LTD. (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| EP-1583744-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1562933-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | Amgen Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |